Core Insights - Kirin Holdings reported strong financial performance for the first nine months of fiscal year 2025, with revenue of 1,756.12 billion yen (approximately 11.3 billion USD), a year-on-year increase of 3.3%, and operating profit of 170.54 billion yen, up 5.2%. Notably, net profit attributable to the parent company surged by 29.7% to 102.83 billion yen, exceeding market expectations [1] Group 1: Business Growth Drivers - The revenue growth of Kirin Holdings is primarily driven by two key pillars: the beer business and the health science business [2] - In the beer segment, Kirin, as the leader in the Japanese beer market, has strengthened its position through product premiumization and channel optimization, with flagship brand "Ichiban Shibori" seeing steady sales growth domestically and a 6% increase in international revenue, particularly in Southeast Asia [2] - The health science segment, focusing on functional beverages and probiotics, has become a new growth driver, with the subsidiary FANCL achieving a 12% revenue increase, contributing over 20% to the group's profits [2] Group 2: Cost Control and Profitability - Despite ongoing pressure from raw material costs and logistics expenses, Kirin has effectively mitigated these challenges through supply chain optimization and digital transformation, resulting in a 0.8 percentage point decrease in sales expense ratio and a 0.5 percentage point decrease in management expense ratio [3] - The overall gross margin improved to 38.7% from 37.2% in the previous year, aided by an increase in the proportion of high-margin health products [3] - The depreciation of the yen has also positively impacted export business, further enhancing overseas profits [3] Group 3: Strategic Acquisitions and Globalization - Kirin's globalization strategy has deepened with two significant acquisitions during the reporting period: a 30% stake in the Vietnamese craft beer brand "Bia Saigon" to strengthen its position in the Southeast Asian beer market, and an increase to 51% ownership in the Australian probiotic research company "BioGaia" to solidify its leadership in microbiome health technology [4] - The management has indicated a focus on the "Asian Growth Corridor" strategy, aiming to leverage Japan as a research center and rapidly penetrate emerging markets like Southeast Asia and India through acquisitions and localized production, with health science revenue expected to reach 40% by 2030 [4] Group 4: Market Outlook - Despite strong performance, Kirin faces challenges such as the long-term decline of the domestic beer market, global supply chain volatility, and intensified competition in the health science sector [5] - The company plans to address these challenges through product innovation, including increased development of non-alcoholic beers and functional beverages, enhancing its sustainable brand image with carbon-neutral beer production lines, and collaborating with top research institutions to deepen studies in microbiome and precision nutrition [5] Conclusion - Kirin Holdings' performance in the first three quarters of fiscal year 2025 validates the effectiveness of its "beer + health" dual-drive strategy, showcasing the resilience of traditional consumer giants amid transformation waves. With ongoing globalization and premiumization efforts, the century-old company is poised to create a second growth curve, demonstrating long-term value potential for global investors [6]

Core Viewpoint - The article discusses a study comparing the effectiveness of three NAD+ supplements: Nicotinamide (Nam), Nicotinamide Riboside (NR), and Nicotinamide Mononucleotide (NMN), highlighting that NR and NMN significantly increase NAD+ levels in humans, while Nam does not show a significant difference compared to a placebo [2][3][9]. Group 1: Study Overview - The study was conducted by Nestlé Health Science and published in Nature Metabolism, focusing on the differential impacts of the three NAD+ boosters on human circulatory NAD+ levels and microbial metabolism [2][3][9]. - A total of 65 healthy participants were randomly assigned to four groups, receiving either NR (1000mg), NMN (1000mg), Nam (500mg), or a placebo for 14 days [9]. Group 2: Results - NR and NMN resulted in a doubling of NAD+ levels in participants, with increases of 49.4μM and 43.1μM respectively, while the Nam group showed no significant difference compared to the placebo group [9]. - The study indicates that the effectiveness of NR and NMN is due to their conversion to nicotinic acid (NA) by gut microbiota, leading to a sustained increase in NAD+ levels [11][12]. Group 3: Mechanism of Action - NR and NMN require gut microbiota for their metabolism, which ensures a gradual and stable increase in NAD+ levels, while Nam is rapidly absorbed, leading to transient effects [11][12]. - The research also highlights that NR and NMN not only enhance NAD+ levels but also promote the growth of beneficial gut bacteria and increase the production of short-chain fatty acids (SCFAs), suggesting dual health benefits [15]. Group 4: Implications for Supplementation - The findings suggest that NR and NMN are superior choices for NAD+ supplementation, emphasizing the need for long-term use to achieve stable effects [15]. - The study underscores the importance of gut microbiota in nutrient metabolism and suggests that personalized supplementation strategies for specific populations, such as the elderly or those with gut dysbiosis, warrant further exploration [15].